Novo Nordisk has forged a strategic partnership with Anthropic, a prominent large-model enterprise, to harness the potential of the research-centric AI platform, Claude Science. This collaboration aims to delve into the utilization of AI in drug research, with a vision to expedite drug discovery and the development of associated software tools. Presently, the integration of AI in the pharmaceutical landscape is broadening its scope from isolated phases of new drug design to encompassing the entire lifecycle, including scientific exploration, data analysis, and clinical progression.

Although the immediate advantages AI offers to the pharmaceutical sector predominantly revolve around the automation of routine tasks, and no AI-originated drugs have secured market approval as of yet, pharmaceutical entities anticipate AI to transcend mere efficiency enhancements. They aspire for AI to aid in unraveling intricate biological conundrums. Novo Nordisk is championing AI through a multifaceted strategy, partnering with pioneering large-model enterprises to infuse AI capabilities, while also forging alliances with biotech firms equipped with AI-propelled drug discovery platforms tailored for specific R&D endeavors. The company perceives AI as instrumental in accelerating pipeline innovation and realizing its medium- to long-term performance aspirations.

Simultaneously, Anthropic is escalating its commitment to the life sciences domain, unveiling a research-oriented AI platform, acquiring biotech ventures, setting up wet laboratories to probe AI-guided robotic biological experiments, and delineating its stance to steer clear of direct rivalry with pharmaceutical firms during the clinical trial phase. Instead, it focuses on empowering them. The function of AI in the pharmaceutical industry has progressively transcended its role as a mere efficiency-boosting tool, and the business demarcations between pharmaceutical companies and AI firms are undergoing redefinition.